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Summary B vitamins have beneficial roles in mental health functional impairments;
however, research on the role of B vitamins in depression among HIV-infected persons is
limited. This study assessed the association between dietary B vitamin intake and depressive symptoms in a cohort of HIV-infected persons. A cross-sectional survey was conducted
among 314 HIV-infected persons (180 men and 134 women) aged 18 to 60 y residing in
the Kathmandu, Nepal. The Beck Depression Inventory-I was used to measure depression,
with a cutoff score of 20 or higher. Dietary intake was assessed using two nonconsecutive 24-h dietary recalls. The relationships between B vitamins and depressive symptoms
were assessed using multiple logistic regression analysis. Twenty-six percent participants
(men: 23%; women: 29%) were depressed. More than two thirds of participants’ B vitamins
intake were below the estimated average requirements (EAR) level. Low intake of riboflavin
was associated with an increased risk of depression in women but not in men. Multivariate OR (95% CI) for depression in the first, second, and third tertiles of riboflavin in total
participants were 1 (reference), 0.87 (0.46–1.64), and 0.49 (0.24–0.98), respectively (p for
trend50.048) and in women were 1 (reference), 0.94 (0.36–2.40), and 0.23 (0.07–0.77),
respectively (p for trend50.020). No clear associations were seen between other B vitamins
and depressive symptoms in either sex. Low intake of riboflavin was independently associated with an increased risk of depressive symptoms in all participants and in HIV-infected
women. Further prospective studies are warranted to confirm the role of vitamin B vitamins
in depressive symptoms among HIV-infected persons.
Key Words B vitamins, depression, diet, HIV, riboflavin

B vitamins have beneficial roles in mental health
functional impairments due to their involvement in
neurochemical pathways in which they regulate the
homocysteine cycle and synthesize monoamines in
the brain (1–9). B vitamins provide various enzymes
required for the metabolism of homocysteine. For example, methylene tetrahydrofolate reductase and flavin
mononucleotide (a coenzyme of riboflavin) and cystathionine-B-synthase and y-cystathionase (pyridoxal
phosphate-dependent enzymes) are involved in the conversion of homocysteine to methionine and cysteine
(1, 2). Methionine has antidepressant properties and is
involved in the synthesis of monoamines in the brain
(10, 11). Thus, a decreased intake of B vitamins may
increase depression due to the accumulation of homocysteine (4–9) and decreased synthesis of monoamines
in the brain (10, 11).
In accordance with these biologic mechanisms, several observational (12–16) and clinical trials (17–19)
have reported a potential benefit of high B vitamin status on decreasing the risk of depression. In the general
population, cross-sectional and prospective studies have
found that low intake of riboflavin (16), pyridoxine (13),
cobalamin (15, 20–22), and folate (12, 23, 24) were
E-mail: kalpana@nursing.umass.edu

associated with increased risk of depression. Furthermore, in patients with depression, studies have reported
low serum or plasma concentrations of pyridoxine (25,
26) and folate (14, 27–29) in depressive patients. High
cobalamin (30) and folate (17–19, 31) status has been
associated with a better response to antidepressant
treatment. Clinical studies (32, 33) also reported an
improved mood disturbance among women with thiamin, riboflavin, and pyridoxine supplementation. Two
systematic reviews (34, 35) of dietary intake and
depression suggested that diet may have a role in the
aetiology of depression; however, there is no strong consistency in the findings across different studies that have
assessed the association between dietary variables and
depression.
Although studies have shown the benefit of B vitamins against depression in the general population and
patients with mental disorders, no published studies
have examined the relationship between B vitamins
and depression in HIV-infected persons. B vitamin deficiency is common among HIV-infected persons due to
malabsorption, diarrhea, impaired storage and altered
metabolism (36–41). Among them, depression is one
of the most common co-morbid conditions (42, 43)
that is associated with higher mortality from both
AIDS-related and non-AIDS related causes (44, 45).
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Studies have shown that serum folate concentrations
were independently associated with hyperhomocysteinemia in HIV-infected persons (46, 47). Thus, this study
aimed to assess the association between B vitamins and
depressive symptoms in persons infected with HIV while
accounting for important HIV-related clinical and other
confounders including anti-retroviral therapy (ART).
As B vitamins have a potential benefit in mental health,
this study hypothesized that a low intake of B vitamins
is associated with depressive symptoms, and tested this
hypothesis in a sample of HIV-infected persons. This
study adds information on the potential benefit of B
vitamins in mental health status among the immunedeficient population, apart from previous studies that
focused mainly on socio-demographic, psychological,
and social risk factors of depression (48).
METHODS
Study design and setting. The present analysis used
baseline data of a longitudinal healthy living study entitled “Positive Living with HIV” (POLH) conducted from
February to March, 2010. This cross-sectional study
was conducted among people living with HIV-infection
in the Kathmandu, Lalitpur, and Bhaktapur districts of
Kathmandu Valley, Nepal. In Nepal, the prevalence of
HIV-infection was 0.3% in the general population and it
was particularly high among risky groups, for example
injecting drug users (IDUs) (6.3%), female sex workers
(4.2%), men who have sex with men (3.8%), and male
labor migrants to India (1.8%), in particular to Mumbai
(49).
Study participants. The study procedures have been
reported in detail elsewhere (50–56). In brief, HIVinfected persons were recruited through the network
of five non-government organizations (NGOs) working
with HIV-infected persons in the Kathmandu Valley. Five
different NGOs were providing need-based care and support services to HIV-infected persons in the Kathmandu
Valley during the study period. These NGOs’ staffs contacted approximately 360 HIV-infected persons either
through phone calls or in person during their visit to
the NGO. Of them, 330 participants made a recruitment
visit, but eight of them did not participate in the study.
All together 322 HIV-positive people, aged between 18
and 60 y, participated in the study voluntarily with
their written informed consent. None of the participants
reported receiving either vitamin or mineral supplementation in previous 12 mo. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the Ethics Committee of
the Nepal Health Research Council, Kathmandu, Nepal;
National Center for Global Health and Medicine, Japan;
and Waseda University, Tokyo, Japan. The study procedures were also approved by the Institutional Review
Board of the University of Massachusetts, Amherst,
USA.
Outcome measure. The Nepali version of the 21-item
Beck Depression Inventory (BDI)-I was used to measure
depressive symptoms experienced over the prior 2 wk
(57, 58). A four-point Likert scale was used to score each
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item, with a total range between 0 and 62 for the instrument. The Nepali version scale was validated in Nepal
with clinical DSM-IV diagnoses (59) of major depressive
disorder (sensitivity 0.73, specificity 0.91; area under
the curve 0.92). The symptoms of 20 and higher are
consistent with moderate to severe depressive symptoms
according to the validation study (57).
Trained interviewers were used to conduct face-toface interviews in a private setting using a structured
pre-tested Nepali version questionnaire. Each interview
lasted about 45–60 min. Interviewers informed all participants about the study procedures using a prepared
information sheet prior to conduct a survey. Participants were requested to sign informed consent forms
prior to being interviewed. Participants were reassured
about the confidentiality of their information.
Dietary assessment. The dietary intake was calculated from 2 24-h dietary recalls 1 wk apart and on
different weekdays. Trained persons collected detailed
information on all food and beverages consumed by
participants in 24 h. The information on food preparation methods and recipes used including brand names
of food products were collected by showing real food
samples and pictures of commonly eaten food. The portion size of food was measured by using locally available
standard spoons, glasses, bowls, food models, recording
recipes, and a diet measurement scale. The daily intake
of B vitamins was calculated using Indian food tables
from the Wfood2 program version 1.0 (60). The intake
of B vitamins was adjusted for energy intake using the
nutrient density method calculated by dividing nutrient
intake by total energy per 1,000 kilo calories (61) and
was categorized into tertiles for analysis.
Covariates measure. A variety of information on
socio-demographic, life-style, cardiovascular risk factors, and ART was collected using the instruments from
previous studies conducted in Nepal (62–65). ART use
was measured by participants’ current use of medication at the time of the survey along with specified duration and names of medication and adherence. The past
history of any disease was solicited by the question
“In the past 12 months, did you suffer from any type
of diseases including minor illnesses?” with response
options of yes or no. If the response was yes, the signs
or symptoms of disease or disease diagnosis with details
of health seeking behavior and treatment of each disease were queried. The measurement of other sociodemographic and life-style variables has been described
elsewhere (66, 67).
Physical examination. The body weight of participant
was measured in kilograms on a digital scale and the
height was measured in centimeters by a stadiometer.
Body mass index (BMI) was calculated as body weight
in kilograms divided by the square of body height in
meters. Blood pressure was measured with the Omron
Automatic Blood Pressure Monitor after the participants
had been seated for at least 10 min with their feet on the
floor and their arms supported at heart level. All anthropometric measurements were repeated to estimate mean
values for these parameters.
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Table 1. Baseline characteristics of HIV-infected persons.
Male
Subjects (n)
Age (mean6SD, y)
Smoking (never, %)
Alcohol consumption (never, %)
Anti-retroviral therapy (yes, %)
History of any disease in past 12 mo (yes, %)
Body mass index (mean6SD, kg/m2)
CD41 T-cell count (median, range; cells/mL)
Energy intake (mean6SD, kcal)
Thiamin (median, range; mg/1,000 kcal)
Riboflavin (median, range; mg/1,000 kcal)
Niacin (median, range; mg/1,000 kcal)
Pyridoxine (median, range; mg/1,000 kcal)
Folic acid (median, range; mg/1,000 kcal)
Cobalamin (median, range; mg/1,000 kcal)

35.60
51
151
119
104
21.49
333
1,985.35
0.36
0.35
5.48
0.69
83.12
0.56

p-value1

Female

180
(6.93)
(28.33)
(83.89)
(66.11)
(57.78)
(2.87)
(41–962)
(600.67)
(0.24–0.79)
(0.17–1.32)
(2.56–9.94)
(0.40–1.40)
(37.48–257.04)
(0.04–3.38)

32.59
115
125
109
94
21.97
360
1,548.34
0.37
0.34
5.32
0.71
80.70
0.49

134
(6.95)
(85.82)
(93.28)
(81.34)
(70.15)
(3.08)
(15–1551)
(443.28)
(0.23–0.80)
(0.16–0.80)
(2.66–9.65)
(0.37–1.52)
(31.75–300.73)
(0.04–3.00)

0.0002
,0.0001
0.011
0.002
0.024
0.157
0.019
,0.0001
0.151
0.116
0.382
0.793
0.745
0.519

Values for B vitamin intake are adjusted for energy intake by using the nutrient density method.
1
p values were based on the Student t test for continuous variables and chi-square test for categorical variables.
Table 2. Correlation coefficients among energy-adjusted B vitamins in HIV-infected participants.
B vitamins

Thiamin

Riboflavin

Niacin

Pyridoxine

Folic acid

Cobalamin

Thiamin1
Riboflavin1
Niacin1
Pyridoxine1
Folic acid2
Cobalamin2

1.000
0.360*
0.719*
0.703*
0.387*
0.202*

0.360*
1.000
0.252*
0.343*
0.401*
0.555*

0.719*
0.252*
1.000
0.715*
0.111**
0.357*

0.703*
0.343*
0.715*
1.000
0.362*
0.343*

0.387*
0.401*
0.111**
0.362*
1.000
0.041**

0.202*
0.555*
0.357*
0.343*
0.041**
1.000

Unit: 1 mg/1,000 kcal, 2 mg/1,000 kcal.
* p,0.001, ** p.0.05.

Statistical analyses. Eight participants who did not
have information on B vitamin intake were excluded,
resulting in a final study population of 314 participants (180 men and 134 women). Student’s t test and
the chi-square test were used to assess the difference
in demographic, life-style, anthropometric, B vitamin
intake, and clinical parameters by depression symptoms, for continuous variables and categorical variables,
respectively.
The relationships between B vitamin intake and
depressive symptoms were assessed using multivariate
logistic regression analysis. Odds ratios and 95% confidence intervals (CI) for depressive symptoms were calculated across tertiles of B vitamin intake. Major sociodemographic characteristics and other confounding
factors having previous establishment or plausible associations with the dependent variable were included as
covariates in the analyses. Age (years, continuous), sex
(men or women), alcohol intake (never or ever), smoking (never or ever), body mass index (kg/m2, continuous), history of any disease in the past 12 mo including minor illnesses (yes or no), CD41 T-cell count (cells/
mL; continuous), and ART (yes or no) were adjusted for
in the multivariate models. The ordinal numbers 0–2
assigned to tertile categories of B vitamin intake were

used to calculate trend associations. All p values were
two-sided and p values less than 0.05 were considered
statistically significant. Analyses were performed with
SAS statistical software version 9.1 (SAS Institute, Inc.,
Cary, NC).
RESULTS
In total, 26% of participants had depressive symptoms. The prevalence of depressive symptoms was
higher in women (29.1%) than in men (23.3%). Table
1 shows the demographic and clinical characteristics
and B vitamin intake of the 314 HIV-infected participants by sex. Men were more likely to smoke or drink
and had a lower median CD41 T-cell count than women.
There were no gender differences in B vitamin intake.
The energy intake in men was significantly higher than
that in women. Table 2 shows the correlation coefficients among B vitamins in HIV-infected participants.
Overall, B vitamins were correlated among each other
except between folic acid and cobalamin, and niacin
and folic acid. There was no significant difference in
demographic or clinical characteristics of participants
by riboflavin intake except for sex and smoking. There
were more men (84/106) and smokers (67/106) in the
highest tertile of riboflavin intake (p,0.05). The mean
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Table 3. Odds ratios and 95% CIs for depressive symptoms according to dietary B vitamin intake in total HIV-infected
participants.
Dietary B-vitamin
p value1

Thiamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Riboflavin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Niacin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Pyridoxine (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Folic acid (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Cobalamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)

T1 (Lowest)

T2

T3 (Highest)

0.29 (0.23–0.33)
24/104
1.00 (reference)
1.00 (reference)
0.26 (0.16–0.30)
30/104
1.00 (reference)
1.00 (reference)
4.11 (2.56–4.74)
30/104
1.00 (reference)
1.00 (reference)
0.57 (0.37–0.65)
27/104
1.00 (reference)
1.00 (reference)
59 (31–71)
25/104
1.00 (reference)
1.00 (reference)
0.22 (0.04–0.32)
24/88
1.00 (reference)
1.00 (reference)

0.36 (0.33–0.40)
27/105
1.15 (0.61–2.17)
1.15 (0.59–2.24)
0.35 (0.30–0.40)
29/105
0.94 (0.51–1.71)
0.87 (0.46–1.64)
5.36 (4.74–5.91)
26/105
0.81 (0.44–1.49)
0.82 (0.43–1.57)
0.69 (0.65–0.75)
29/105
1.08 (0.59–2.00)
1.02 (0.54–1.94)
82 (71–99)
28/105
1.14 (0.61–2.14)
1.35 (0.70–2.61)
0.50 (0.32–0.75)
25/105
0.83 (0.43–1.59)
0.74 (0.37–1.47)

0.46 (0.40–0.80)
30/105
1.33 (0.71–2.48)
1.22 (0.64–2.33)
0.44 (0.40–1.32)
22/105
0.65 (0.34–1.23)
0.49 (0.24–0.98)
6.89 (5.93–9.94)
25/105
0.77 (0.41–1.43)
0.74 (0.39–1.42)
0.86 (0.75–1.52)
25/105
0.89 (0.47–1.66)
0.75 (0.39–1.46)
129 (99–300)
28/105
1.14 (0.61–2.14)
1.08 (0.56–2.09)
1.16 (0.75–3.38)
28/105
0.97 (0.51–1.83)
0.85 (0.43–1.67)

0.364
0.545
0.192
0.048
0.406
0.373
0.721
0.406

0.664
0.798

0.948
0.671

Values for B-vitamin intake are medians for adjusted energy intake by using the nutrient density method for each tertile.
1
Linear trends across tertiles of B-vitamin intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2
All multivariate models were adjusted for age (years, continuous), sex (men or women), alcohol intake (never or ever),
smoking (never or ever), body mass index (kg/m2, continuous), history of any disease in past 12 mo (yes or no), CD41 T-cell
count (200 or .200; cells/mL), and anti-retroviral therapy (yes or no).

energy intake and all B-vitamins were significantly
higher in the highest tertile of riboflavin intake than
that of the lowest tertile (p,0.05): energy (2183.60
vs 1367.60 kcal), thiamin (0.83 vs 0.52 mg/1,000
kcal), riboflavin (0.95 vs 0.40 mg/1,000 kcal), niacin
(12.40 vs 7.30 mg/1,000 kcal), pyridoxine (1.59 vs
1.00 mg/1,000 kcal), folic acid (200.60 vs 122.60
mg/1,000 kcal), and cobalamin (1.84 vs 0.60 mg/
1,000 kcal) (data not shown in the table).
This study did not find any statistically significant associations between B vitamin intake and the prevalence of
depressive symptoms in total participants except for the
intake of riboflavin (Table 3). The multivariate adjusted
OR (95% CI) for depressive symptoms was 1 (reference),
0.87 (0.46–1.64) and 0.49 (0.24–0.98), respectively,
for successive tertiles of energy-adjusted riboflavin
intake (p for trend50.048). Table 4 shows the association between tertiles of B vitamin intake and depressive symptoms among men. No significant association
was observed between B vitamins intake and depressive
symptoms in men. But a significant inverse association
between energy-adjusted riboflavin intake and depressive symptoms was found among women (Table 5). The
multivariate adjusted OR (95% CI) for depressive symptoms in women was 1 (reference), 0.94 (0.36–2.40) and

0.23 (0.07–0.77), respectively, for successive tertiles of
energy-adjusted riboflavin intake (p for trend50.020).
DISCUSSION
Among six different B vitamins, only low dietary
intake of riboflavin was significantly associated with
increased risk of depressive symptoms in HIV-infected
women. This is the first study that has assessed the
role of B vitamins in depressive symptoms among HIVinfected persons adjusting for important confounding
variables.
The relationship between dietary riboflavin intake
and depression has received little attention although the
protective role of riboflavin intake in depression is recognized (1, 2). This study adds the beneficial role of riboflavin against depressive symptoms among the immunedeficient population with poor nutritional status. This
finding is supported by previous observational study
conducted among the general population in a developed
country (16). For example, in the Osaka Maternal and
Child Health Study (16), a decreased risk of postpartum
depression was observed among Japanese women in the
third quartile of riboflavin intake as compared to the
first. In a study from Calgary (68), riboflavin and other
B vitamins were significantly correlated with Global
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Table 4. Odds ratios and 95% CIs for depressive symptoms according to dietary B vitamin intake in HIV-infected men.
Dietary B vitamins
p value1

Thiamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Riboflavin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Niacin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Pyridoxine (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Folic acid (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Cobalamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)

T1 (Lowest)

T2

0.29 (0.24–0.32)
15/60
1.00 (reference)
1.00 (reference)
0.27 (0.17–0.30)
14/60
1.00 (reference)
1.00 (reference)
4.12 (2.56–4.69)
18/60
1.00 (reference)
1.00 (reference)
0.57 (0.40–0.64)
16/60
1.00 (reference)
1.00 (reference)
62.42 (37.48–73.01)
11/60
1.00 (reference)
1.00 (reference)
0.24 (0.04–0.36)
15/56
1.00 (reference)
1.00 (reference)

0.36 (0.32–0.39)
14/60
0.93 (0.39–2.10)
0.92 (0.37–2.28)
0.35 (0.30–0.40)
13/60
0.90 (0.38–2.14)
0.99 (0.39–2.49)
5.48 (4.74–6.09)
12/60
0.58 (0.25–1.35)
0.52 (0.21–1.27)
0.69 (0.65–0.75)
14/60
0.83 (0.36–1.91)
0.79 (0.32–1.94)
83.12 (73.09–93.64)
17/60
1.76 (0.74–4.16)
2.52 (0.98–6.50)
0.56 (0.36–0.83)
10/60
0.54 (0.22–1.34)
0.60 (0.22–1.57)

T3 (Highest)
0.45 (0.40–0.79)
13/60
0.83 (0.35–1.93)
0.84 (0.34–2.05)
0.49 (0.40–1.32)
15/60
1.09 (0.47–2.52)
1.07 (0.42–2.74)
6.96 (6.21–9.94)
12/60
0.58 (0.25–1.35)
0.52 (0.21–1.28)
0.86 (0.75–1.48)
12/60
0.68 (0.29–1.61)
0.62 (0.24–1.57)
128.77 (94.77–257.04)
14/60
1.35 (0.55–3.28)
1.27 (0.49–3.25)
1.19 (0.84–63.38)
17/60
1.08 (0.47–2.44)
1.11 (0.46–2.68)

0.666
0.702
0.829
0.875
0.197
0.148
0.388
0.318

0.517
0.656

0.819
0.761

Values for B vitamin intake are adjusted for energy intake by using the nutrient density method for each tertile.
Linear trends across tertiles of B vitamins intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2
All multivariate models were adjusted for age (years, continuous), alcohol intake (never or ever), smoking (never or ever),
body mass index (kg/m2, continuous), history of any disease in past 12 mo (yes or no), CD41 T-cell count (200 or .200;
cells/mL), and anti-retroviral therapy (yes or no).
1

Assessment of Functioning (GAF) scores among 97
community-based adults with mood disorders. A clinical
trial among 120 healthy adults with supplementation
of 10 times the recommended daily dose of 9 vitamins,
or a placebo, reported an improved mood disturbance
among women with thiamin, riboflavin, and pyridoxine
supplementation (32, 33).
The benefit of riboflavin on mental health may be
explained by the action of riboflavin coenzymes in the
remethylation and trans-sulfuration of homocysteine, as discussed earlier (1, 2). Jacques et al. (8) in the
Framingham Study population and Ganji and Kafai (9)
in the National Health and Nutrition Examination Survey population reported an inverse relationship between
riboflavin and homocysteine. Thus, hyperhomocysteinemia may mediate the relationship between increased
intake of riboflavin and the decreased risk of depression.
This study did not find any significant decreased risk of
depressive symptoms with increased intake of thiamin,
niacin, pyridoxine, cobalamin, or folate in HIV-infected
persons. The findings are both consistent with (16, 24,
69–71) and contrary to some previous studies (12–16,
72–75) that assessed the relationship between thiamin,
niacin, pyridoxine, cobalamin, or folate and depression
in the general population living in developed countries.
These discrepancies may be partly ascribed to differ-

ences in the target population, dietary intake, dietary
assessment methods, depressive symptoms measurement methods, and confounding variables treatment.
In this study cohort, more than two-thirds of the participants’ intake of B vitamins was below the estimated
average requirements (EAR) level (76). The majority
of participants’ B vitamin intakes were below the EAR
level; 86.67% for thiamin (,1.0 mg/d), 90.0% for
riboflavin (,1.1 mg/d), 65.0% for niacin (,12 mg/d),
24.44% for pyridoxine (,1.1 mg/d), 78.41% for cobalamin (,2.0 mg/d), and 97.78% for folate (,320 mg/d) in
men and 94.03% for thiamin (,0.9 mg/d), 93.28% for
riboflavin (,0.9 mg/d), 88.06% for niacin (,11 mg/d),
54.48% for pyridoxine (,1.1 mg/d), 88.52% for cobalamin (,2.0 mg/d), and 99.25% for folate (,320 mg/d)
in women. Even the median intake of these B vitamins
for the participants in the highest tertiles was below the
EAR level. It is very likely that the ranges of B vitamin
intake are not sufficient to make an association between
B vitamins and depression. However, an inverse relationship between only riboflavin and depressive symptoms in this study was significant in all participants
and in women. The prevalence of depressive symptoms
in the highest tertile of riboflavin (20.95%) was lower
than that in the highest tertiles of other B vitamins in
all participants (thiamin: 28.57%; niacin: 23.80%; pyri-
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Table 5.

Odds ratios and 95% CIs for depressive symptoms according to dietary B vitamin intake in HIV-infected women.
Dietary B vitamins
p value1

Thiamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Riboflavin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Niacin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Pyridoxine (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Folic acid (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)
Cobalamin (median, range; mg/1,000 kcal)
No. with depression
   Univariate model OR (95% CI)
  Multivariate model2 OR (95% CI)

T1 (Lowest)

T2

T3 (Highest)

0.30 (0.23–0.34)
12/44
1.00 (reference)
1.00 (reference)
0.25 (0.16–0.30)
15/44
1.00 (reference)
1.00 (reference)
3.97 (2.66–4.74)
12/44
1.00 (reference)
1.00 (reference)
0.56 (0.37–0.65)
10/44
1.00 (reference)
1.00 (reference)
58.69 (31.75–68.51)
13/44
1.00 (reference)
1.00 (reference)
0.13 (0.04–0.27)
10/32
1.00 (reference)
1.00 (reference)

0.37 (0.34–0.40)
11/45
0.86 (0.33–2.23)
0.88 (0.31–2.44)
0.34 (0.30–0.39)
16/45
1.06 (0.44–2.55)
0.94 (0.36–2.40)
5.31 (4.76–5.80)
13/45
1.08 (0.43–2.73)
1.31 (0.49–3.48)
0.73 (0.65–0.76)
15/45
1.70 (0.66–4.34)
1.45 (0.54–3.86)
80.18 (68.56–101.52)
12/45
0.86 (0.34–2.18)
0.95 (0.36–2.53)
0.45 (0.27–0.67)
13/45
0.89 (0.33–2.39)
0.80 (0.27–2.36)

0.48 (0.41–0.80)
16/45
1.47 (0.59–3.60)
1.47 (0.57–3.81)
0.47 (0.39–0.80)
8/45
0.41 (0.15–1.12)
0.23 (0.07–0.77)
6.65 (5.82–9.65)
14/45
1.20 (0.48–3.00)
1.29 (0.49–3.37)
0.86 (0.76–1.52)
14/45
1.53 (0.59–3.95)
1.28 (0.48–3.45)
130.68 (101.89–300.73)
14/45
1.07 (0.43–2.66)
1.08 (0.41–2.83)
1.12 (0.68–3.00)
12/45
0.80 (0.29–2.16)
0.55 (0.17–1.71)

0.387
0.411
0.091
0.020
0.690
0.602
0.387
0.635

0.868
0.864

0.660
0.292

Values for B vitamin intake are adjusted for energy intake by using the nutrient density method for each tertile.
Linear trends across tertiles of B vitamins intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2
All multivariate models were adjusted for age (years, continuous), alcohol intake (never or ever), smoking (never or ever),
body mass index (kg/m2, continuous), history of any disease in past 12 mo (yes or no), CD41 T-cell count (200 or .200;
cells/mL), and anti-retroviral therapy (yes or no).
1

doxine: 23.80%; folic acid: 26.66; cobalamin: 26.66%).
Similarly, the prevalence of depressive symptoms in
the highest tertile of riboflavin (17.70%) was lower
than that in the highest tertiles of other B vitamins in
women (thiamin: 35.55%; niacin: 31.11%; pyridoxine:
31.11%; folic acid: 31.11; cobalamin: 26.66%). Thus,
the level of riboflavin in the highest tertile of riboflavin was perhaps above the threshold where riboflavin’s
effects on depression could be seen. Further prospective
studies are needed to assess the effects of B vitamins in
the risk of depression.
Regarding sources of B vitamins, significant contributors to the B vitamin intake in the Nepalese diet are rice
and cereals (77). The common sources of B vitamins
in the Nepalese diet are rice (B1, B2), wheat bread (B1,
B9), pulse/lentils (B1, B6, B9), navy beans (B1), blackeyed peas (B9), green peas (B1, B3), mushrooms (B2,
B3), spinach (B2, B6, B9), broccoli (B9), lettuce (B9),
dried fruits (B6), bananas (B6), mango (B9), oranges
(B9), tofu (B12), low-fat dairy products and cheese (B2,
B12), egg (B2, B12), chicken (B3, B6), liver (B3), red
meat (B2, B12), tuna fish (B6), and trout (B1) (77). The
mean daily consumption of food averaged 4586107 g
of cereals, 436697 g of rice, 1736127 g of colored
vegetables, 1016191 g of milk and dairy products, and
60686 g of potatoes (77). These items constituted more

than three-fourths of the total food weight, whereas the
amounts and frequency of the consumption of meat
(19643 g), fish (13632 g) and eggs (2614 g) were
very low.
The present study had some limitations. First, the
cross-sectional design of the study does not rule out the
possibility of reverse causality and that depressive symptoms may influence B vitamin intake. Second, depression was measured using the BDI scale in our study.
Though clinical diagnosis is the gold standard, such an
approach is not feasible in community-based studies.
The BDI has been validated in the context of this study
and has been widely used in epidemiologic studies (78,
79). Third, a 24 h recall may not provide good estimates
of usual dietary intake because of within-person variation. However, this would be less relevant in the present study population due to the measurement of dietary
recalls twice, 1 wk apart, and to the limited variation
of dietary intake, as some studies suggest that dietary
habits tend to remain stable over time (24, 80). Fourth,
hypohomocysteinemia may mediate the relationship
between increased intake of riboflavin and the decreased
risk of depression as studies have reported (8, 9) an
inverse relationship between riboflavin and homocysteine. However, the homocysteine level of participants
was not measured in this study. Fifth, the possibility of

394

Poudel-Tandukar K

residual confounding cannot be excluded although we
adjusted for known factors that could influence both B
vitamin intake and depressive symptoms. Finally, study
participants were not selected using a random sampling
method; thus caution should be taken in generalizing our study findings to the entire population of HIVinfected persons in the country.
In conclusion, the present study suggests that higher
intake of riboflavin may be associated with low depressive symptoms in all participants and in HIV-infected
women even after taking account of ART and other
important confounding factors. This finding adds the
importance of B vitamins in the mental health status of
HIV-infected persons. Further prospective studies and/
or clinical trials are needed to confirm the role of B vitamins in depression in HIV-infected persons.
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